The global clinical nutrition market is on track to reach $104.7 billion by 2031, according to a new industry forecast, propelled by converging pressures: a rapidly aging global population, rising prevalence of chronic disease, escalating healthcare system investment, and a steady cadence of finished-formulation advances from ingredient suppliers and CPG manufacturers alike.
Who's Driving Demand
Three patient populations sit at the center of projected growth. Older adults represent the largest and fastest-expanding segment — age-related sarcopenia, dysphagia, and general malnutrition create sustained demand for high-protein, micronutrient-dense oral nutritional supplements (ONS) and tube-feeding products. Oncology patients constitute a second major cohort; cachexia management and peri-operative nutritional support have become standard-of-care targets, with clinical dietitians increasingly specifying condition-specific formulas that deliver precise macronutrient ratios and evidence-backed functional ingredients such as omega-3 fatty acids, beta-hydroxy beta-methylbutyrate (HMB), and branched-chain amino acids (BCAAs). Pediatric and infant malnutrition rounds out the demand picture, particularly across emerging markets where healthcare infrastructure investment is accelerating.
For ingredient suppliers, the forecast signals a durable runway. Bioavailability-optimized mineral forms, standardized botanical extracts, and next-generation protein fractions — including hydrolyzed collagen peptides and plant-based isolates — are increasingly finding application in clinical-grade SKUs. The shift toward condition-specific formulations also intensifies scrutiny of clinical endpoints: operators sourcing ingredients for clinical nutrition applications are asking for double-blind, placebo-controlled trial data, not merely structure-function claims.
Formulation and Regulatory Tailwinds
Regulatory clarity is another growth enabler. In the United States, medical foods occupy a distinct statutory category under FDAMA, allowing condition-specific labeling that general dietary supplements cannot carry. That distinction is drawing investment from both legacy healthcare nutrition brands and better-for-you CPG entrants looking to develop products positioned at the clinical-consumer interface — think high-protein, low-sugar ONS formats that straddle the pharmacy and specialty-retail channels. The GLP-1 weight-management wave adds a parallel tailwind: patients on semaglutide and tirzepatide face significant lean-mass loss risk, creating a new clinical nutrition sub-segment focused on muscle preservation and micronutrient repletion.
For operators and co-manufacturers, the category's growth trajectory reinforces investment in pharmaceutical-grade quality systems, including cGMP compliance, third-party verification, and allergen-controlled production environments — requirements that raise barriers to entry but reward established supply-chain partners. Brands active in protein and sports nutrition or gut health and probiotics are increasingly adjacent to the clinical nutrition opportunity, as evidence bases for microbiome modulation and protein sufficiency expand into institutional care settings.
The $104.7 billion projection reflects a market maturing beyond commodity formulation into a precision-nutrition paradigm — one where clinical evidence, bioavailability data, and condition-specific positioning increasingly determine shelf placement, formulary inclusion, and ultimately, patient outcomes.
Written by Michael Politz, Author of Guide to Restaurant Success: The Proven Process for Starting Any Restaurant Business From Scratch to Success (ISBN: 978-1-119-66896-1), Founder of Food & Beverage Magazine, the leading online magazine and resource in the industry. Designer of the Bluetooth logo and recognized in Entrepreneur Magazine's "Top 40 Under 40" for founding American Wholesale Floral, Politz is also the Co-founder of the Proof Awards and the CPG Awards and a partner in numerous consumer brands across the food and beverage sector.
